SCHEMBL5451368

SCHEMBL5451368

NC(=O)c1c(NC(=O)Nc2cc(C(F)(F)F)ccc2Cl)sc2c1CCSC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.47
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
FLT3 P36888 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TRPV1 Q8NER1 1/20 0.41
KCNH2 Q12809 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447615 0.87 FLT3 (0.56) CHRNA7MAPTMEN1KMT2AALDH1A1
SCHEMBL5457788 0.84 PTPN1 (0.45) MAPTGAALMNAKDM4EMEN1
SCHEMBL5454155 0.84 KCNH2 (0.49) MAPTGAALMNAKDM4EMEN1
SCHEMBL5459988 0.84 ANO1 (0.53) CHRNA7MAPTTP53GAALMNA
SCHEMBL5456002 0.83 KDR (0.53) MAPTLMNAKDM4EMEN1USP2
SCHEMBL5462800 0.83 KMT2A (0.48) MAPTTP53GAALMNAKDM4E
SCHEMBL5449415 0.80 MEN1 (0.64) MAPTLMNAKDM4EMEN1USP2
SCHEMBL5450963 0.80 KCNH2 (0.50) MAPTLMNAKDM4EMEN1USP2
SCHEMBL5449213 0.79 LMNA (0.48) MAPTLMNAKDM4EMEN1USP2
SCHEMBL5453522 0.79 MEN1 (0.55) MAPTGAALMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CHRNA7 669/4885MAPT 21/4885TP53 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.